Company Encyclopedia
View More
name
Inozyme Pharma
INZY.US
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products.
1.946 T
INZY.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth

    Biomarin Pharmaceutical Inc. is pursuing an acquisition strategy, including the recent purchase of Inozyme, which poses significant business risks. These risks include potential management distraction, high costs, and challenges in integrating operations, which may affect financial performance and stakeholder relationships. The success of acquired products is uncertain, possibly requiring more resources than anticipated. Despite these challenges, Wall Street maintains a Strong Buy consensus on BMRN stock, with 18 Buys and 4 Holds.

    Tip Ranks·
    US
    BMRN
    -0.90%
    US
    INZY
    0.00%
    Tip Ranks·
    US
    BMRN
    -0.90%
    US
    INZY
    0.00%

    BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025

    BioMarin Pharmaceutical Inc. anticipates a charge of approximately $221 million in Q3 2025 due to its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is expected to affect both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. The figures are preliminary and subject to final financial statement procedures for the quarter ending September 30, 2025.

    Reuters·
    US
    BMRN
    -0.90%
    US
    INZY
    0.00%
    Reuters·
    US
    BMRN
    -0.90%
    US
    INZY
    0.00%

    Inozyme Pharma Inc. Announces Delisting from Nasdaq and Deregistration of Shares Following Merger

    Inozyme Pharma Inc. has announced its delisting from Nasdaq and deregistration of shares following a merger, effective July 1, 2025. The company has requested Nasdaq to file a Form 25 with the SEC to remove its shares from listing and intends to file a Form 15 to terminate registration and suspend reporting obligations under the Securities Exchange Act of 1934. This marks a significant regulatory move in Inozyme's corporate trajectory post-merger.

    Reuters·
    US
    INZY
    0.00%
    Reuters·
    US
    INZY
    0.00%

    Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders | INZY Stock News

    Inozyme Pharma, Inc. has postponed its 2025 Annual Meeting of Stockholders, originally set for June 25, 2025, due to its acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, there will be no meeting for public stockholders. If not, the Board will reconvene the meeting at a later date. Inozyme is focused on developing therapies targeting the PPi-Adenosine Pathway, with its lead therapy INZ-701 in late-stage clinical development for ENPP1 Deficiency.

    StockTitan·
    US
    INZY
    0.00%
    StockTitan·
    US
    INZY
    0.00%

    Halper Sadeh LLC is investigating INZY, SVT, HLGN for securities laws violations.

    On June 12, 2025, Halper Sadeh LLC, an investor rights law firm, disclosed an ongoing investigation into select companies. Inozyme Pharma, Inc. (NASDAQ: INZY) is one of the companies under scrutiny for potential infringements of federal securities laws or breaches of fiduciary responsibilities towards shareholders. The investigation aims to address issues impacting shareholder interests within these companies.

    Unusual Whales·
    US
    INZY
    0.00%
    Unusual Whales·
    US
    INZY
    0.00%
    © 2025 Longbridge｜Disclaimer